Список литературы к Главе 10

1. Campo E. et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications // Blood. 2011. Vol. 117, N 19. P. 5019–5032.

2. Johansson P. et al. Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia // Leuk. Res. 2010. Vol. 34, N 7. P. 892–898.

3. Marti G.E. et al. Diagnostic criteria for monoclonal B­cell lymphocytosis // Br. J. Haematol. 2005. Vol. 130, N 3. P. 325–332.

4. Strati P., Shanafelt T.D. Monoclonal B­cell lymphocytosis and early­stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification // Blood. 2015. Vol. 126, N 4. P. 454–462.

5. Rawstron A.C. et al. Monoclonal B­cell lymphocytosis and chronic lymphocytic leukemia // N. Engl. J. Med. 2008. Vol. 359, N 6. P. 575–583.

6. Moreau E.J. et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b) // Am. J. Clin. Pathol. 1997. Vol. 108, N 4. P. 378-382.

7. Ginaldi L. et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias // J. Clin. Pathol. 1998. Vol. 51, N 5. P. 364–369.

8. Matutes E. et al. The immunological profile of B­cell disorders and proposal of a scoring system for the diagnosis of CLL // Leukemia. 1994. Vol. 8, N 10. P. 1640–1645.

9. Morice W.G. et al. Predictive value of blood and bone marrow flow cytometry in B­cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients // Mayo Clin. Proc. 2008. Vol. 83, N 7. P. 776–785.

10. Rawstron A.C. et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project // Cytometry B Clin. Cytom. 2018. Vol. 94, N 1. P. 121–128.

11. Orchard J.A. et al. ZAP­70 expression and prognosis in chronic lymphocytic leukaemia // Lancet. 2004. Vol. 363, N 9403. P. 105–111.

12. Crespo M. et al. ZAP­70 expression as a surrogate for immunoglobulin­variable-region mutations in chronic lymphocytic leukemia // N. Engl. J. Med. 2003. Vol. 348, N 18. P. 1764–1775.

13. Rassenti L.Z. et al. ZAP­70 compared with immunoglobulin heavy­chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia // N. Engl. J. Med. 2004. Vol. 351, N 9. P. 893–901.

14. Ibrahim S. et al. CD38 expression as an important prognostic factor in B­cell chronic lymphocytic leukemia // Blood. 2001. Vol. 98, N 1. P. 181–186.

15. Lin K. et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia // Blood. 2002. Vol. 100, N 4. P. 1404–1409.

16. Ghia P. et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression // Blood. 2003. Vol. 101, N 4. P. 1262–1269.

17. Boonstra J.G. et al. CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B­CLL): comparison of three approaches to analyze its expression // Cytometry B Clin. Cytom. 2006. Vol. 70, N 3. P. 136–141.

18. Kröber A. et al. Additional genetic high­risk features such as 11q deletion, 17p deletion, and V3­21 usage characterize discordance of ZAP­70 and VH mutation status in chronic lymphocytic leukemia // J. Clin. Oncol. 2006. Vol. 24, N 6. P. 969–975.

19. Bulian P. et al. CD49d is the strongest flow cytometry­based predictor of overall survival in chronic lymphocytic leukemia // J. Clin. Oncol. 2014. Vol. 32, N 9. P. 897–904.

20. Dal Bo M. et al. Functional and clinical significance of the integrin alpha chain CD49d expression in chronic lymphocytic leukemia // Curr. Cancer Drug Targets. 2016. Vol. 16, N 8. P. 659–668.

21. Hallek M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL // Blood. 2018. Vol. 131, N 25. P. 2745–2760.

22. National Comprehensive Cancer Network. Chronic lymphocytic leukemia (Version 2, 2019). 2019 April. URL: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/pro­ fessionals/physician_gls/pdf/cll.pdf

23. Eichhorst B. et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow­up // Ann. Oncol. 2021. Vol. 32, N 1. P. 23–33.

24. Абдурахманов Д.Т., Абузарова Г.Р., Агеева Т.А., Алексеев С.М., Аль­Ради Л.С., Асланиди И.П. и др. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Москва : Буки Веди, 2018.

25. Jain P. et al. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single­group, phase 2 trial // Lancet Haematol. 2017. Vol. 4, N 2. P. e67–e74.

26. Cramer P. et al. Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual // Leuk. Res. 2014. Vol. 38, N 3. P. 284–285.

27. Schroeder H.W. Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire // Immunol. Today. 1994. Vol. 15, N 6. P. 288–294.

28. Fais F. et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors // J. Clin. Invest. 1998. Vol. 102, N 8. P. 1515–1525.

29. Hashimoto S. et al. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells // J. Exp. Med. 1995. Vol. 181, N 4. P. 1507–1517.

30. Damle R.N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 6. P. 1840–1847.

31. Hamblin T.J. et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 6. P. 1848–1854.

32. Rossi D. et al. Molecular prediction of durable remission after first­line fludarabine­cyclophosphamide­rituximab in chronic lymphocytic leukemia // Blood. 2015. Vol. 126, N 16. P. 1921–1924.

33. Fischer K. et al. Long­term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial // Blood. 2016. Vol. 127, N 2. P. 208–215.

34. Thompson P.A. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long­term disease­free survival in IGHV­mutated chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 3. P. 303–309.

35. Stamatopoulos K. et al. Antigen receptor stereotypy in chronic lymphocytic leukemia // Leukemia. 2017. Vol. 31, N 2. P. 282–291.

36. Baliakas P. et al. Not all IGHV3­21 chronic lymphocytic leukemias are equal: prognostic considerations // Blood. 2015. Vol. 125, N 5. P. 856–859.

37. Döhner H. et al. Genomic aberrations and survival in chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343, N 26. P. 1910–1916.

38. Pospisilova S. et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia // Leukemia. 2012. Vol. 26, N 7. P. 1458–1461.

39. Grever M.R. et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997 // J. Clin. Oncol. 2007. Vol. 25, N 7. P. 799–804.

40. Stilgenbauer S. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial // Blood. 2014. Vol. 123, N 21. P. 3247–3254.

41. Zenz T. et al. TP53 mutation and survival in chronic lymphocytic leukemia // J. Clin. Oncol. 2010. Vol. 28, N 29. P. 4473–4479.

42. Shanafelt T.D. et al. Prospective evaluation of clonal evolution during long­term follow­up of patients with untreated early­stage chronic lymphocytic leukemia // J. Clin. Oncol. 2006. Vol. 24, N 28. P. 4634–4641.

43. Buhmann R. et al. CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B­cell chronic lymphocytic leukaemia cells // Br. J. Haematol. 2002. Vol. 118, N 4. P. 968–975.

44. Mayr C. et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia // Blood. 2006. Vol. 107, N 2. P. 742–751.

45. Haferlach C. et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping // Leukemia. 2007. Vol. 21, N 12. P. 2442–2451.

46. Baliakas P. et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact // Blood. 2019. Vol. 133, N 11. P. 1205–1216.

47. Thompson P.A. et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib­based regimens // Cancer. 2015. Vol. 121, N 20. P. 3612–3621.

48. Herling C.D. et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil­based chemotherapy or chemoimmunotherapy // Blood. 2016. Vol. 128, N 3. P. 395–404.

49. Wierda W.G. et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia // Blood. 2007. Vol. 109, N 11. P. 4679–4685.

50. Pflug N. et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia // Blood. 2014. Vol. 124, N 1. P. 49–62.

51. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL­IPI): a meta­analysis of individual patient data // Lancet Oncol. 2016. Vol. 17, N 6. P. 779–790.

52. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial // N. Engl. J. Med. 1988. Vol. 319, N 14. P. 902–907.

53. Boughton B.J. et al. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia // Clin. Lab. Haematol. 1995. Vol. 17, N 1. P. 75–80.

54. Molica S. et al. Prophylaxis against infections with low­dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study // Haematologica. 1996. Vol. 81, N 2. P. 121–126.

55. Raanani P. et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta­analysis // Leuk. Lymphoma. 2009. Vol. 50, N 5. P. 764–772.

56. Sklenar I. et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma // Oncology. 1993. Vol. 50, N 6. P. 466–477.

57. Kim H.Y., Kim W. Chemotherapy­related reactivation of hepatitis B infection: updates in 2013 // World J. Gastroenterol. 2014. Vol. 20, N 40. P. 14 581–14 588.

58. Yazici O., Sendur M.A., Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies // World J. Gastroenterol. 2014. Vol. 20, N 22. P. 6716–6724.

59. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia // Blood. 1975. Vol. 46, N 2. P. 219–234.

60. Binet J.L. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. 1981. Vol. 48, N 1. P. 198–206.